Cube Pharmaceutical announced that the company recently received the “Notice of Approval of Application for the Marketing of Chemical Ingredients” for cloprocaine hydrochloride issued by the State Drug Administration. The application was an application for the marketing of chemical raw materials produced domestically. The approval conclusion was that it complied with the relevant requirements for drug registration and approved registration. The notice was valid until October 11, 2031. Because it is a local anesthetic, cloproca hydrochloride is not addictive, and is not a drug specially controlled by the country. As of the date of this announcement, in addition to the company, 4 companies for this API have a registration status of “A” and 5 companies have a registration status of “I”. This approval will further enrich the company's narcotic drug API product pipeline.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.